Perspective Therapeutics
CATX
26 hedge funds and large institutions have $1.86M invested in Perspective Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
48% more capital inflows, than outflows
Capital inflows: $59K | Capital outflows: $40K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.01% less ownership
Funds ownership: 6.56% → 6.55% (-0.01%)
4% less funds holding
Funds holding: 27 → 26 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$23.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.47K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.37K |
| 5 |
BlackRock
New York
|
+$1.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$12K |
| 3 |
SIM
Sonora Investment Management
Tucson,
Arizona
|
-$3.13K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$1.71K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.12K |
CATX Hedge Fund Activity: Q3 2017 in Review
26 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2017, worth a combined $1.86M — down 18% from $2.25M a quarter earlier.
Fund positioning in CATX was balanced in Q3 2017: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $23.9K. The largest seller was Vanguard Group, cutting an estimated $22K.
- 26 institutional investors held Perspective Therapeutics (CATX) as of Q3 2017, down from 27 in Q2 2017.
- Funds reported $1.86M of Perspective Therapeutics stock for Q3 2017, down 18% quarter-over-quarter.
- 3 funds opened new Perspective Therapeutics positions in Q3 2017 and 3 closed out, a net change of 0 holders.
- The largest Perspective Therapeutics buyer in Q3 2017 was Virtu Financial, an estimated $23.9K added.
- The largest Perspective Therapeutics seller in Q3 2017 was Vanguard Group, an estimated $22K sold.
Based on aggregated 13F filings for Q3 2017.